Published in Clin Exp Nephrol on July 18, 2013
Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant (2014) 1.55
Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics (2014) 1.14
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. Drugs Context (2015) 0.81
Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol (2014) 0.78
Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan. CEN Case Rep (2015) 0.75
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis (2002) 81.62
Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis (2009) 18.60
Autosomal dominant polycystic kidney disease. Lancet (2007) 8.55
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med (2010) 4.36
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Nephron adaptation to renal injury or ablation. Am J Physiol (1985) 2.65
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int (2008) 1.84
Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2011) 1.62
Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assist Tomogr (2000) 1.58
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol (2006) 1.37
Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.32
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.21
Rate of functional deterioration in polycystic kidney disease. Kidney Int (1983) 1.19
Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease. Am J Kidney Dis (2004) 1.19
Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron (1998) 1.09
Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2012) 0.88
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Initial operative experience of single-port retroperitoneal laparoscopic nephrectomy. Int J Urol (2012) 1.39
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol (2009) 1.15
Supine versus prone position during percutaneous nephrolithotomy: a report from the clinical research office of the endourological society percutaneous nephrolithotomy global study. J Endourol (2011) 1.07
Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol (2010) 0.97
Laparoscopic management of urachal remnants in adulthood. Int J Urol (2006) 0.96
Prostatic cyst arising around the bladder neck-cause of bladder outlet obstruction: two case reports. Hinyokika Kiyo (2007) 0.92
[Comparison of clinical results between TUR-P and holmium laser enucleation of the prostate (HoLEP) based on the initial experience]. Nihon Hinyokika Gakkai Zasshi (2008) 0.91
Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol (2006) 0.91
Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2012) 0.88
Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis. Hum Cell (2008) 0.88
Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol (2010) 0.87
The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD. Nephrol Dial Transplant (2008) 0.86
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol (2007) 0.86
Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. Int J Urol (2010) 0.85
Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients. Int J Urol (2004) 0.84
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther (2007) 0.84
Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents. J Urol (2002) 0.82
Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. J Urol (2004) 0.81
Evaluation of 2,590 urological laparoscopic surgeries undertaken by urological surgeons accredited by an endoscopic surgical skill qualification system in urological laparoscopy in Japan. Surg Endosc (2011) 0.80
Oncological outcome of retroperitoneoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. Int J Urol (2006) 0.80
Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer. Int J Urol (2009) 0.80
Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease. Nephron (2015) 0.80
Predictors of septic shock in obstructive acute pyelonephritis. World J Urol (2013) 0.79
Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol (2014) 0.78
Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. Jpn J Clin Oncol (2014) 0.78
Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. BMC Res Notes (2014) 0.78
The effect of eicosapentaenoic acid on prostate-specific antigen. In Vivo (2006) 0.77
[Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor]. Nihon Hinyokika Gakkai Zasshi (2013) 0.76
Effects of eicosapentaenoic acid on biochemical failure after radical prostatectomy for prostate cancer. In Vivo (2010) 0.76
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol (2005) 0.76
A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy. Anticancer Res (2009) 0.75
Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a single-center experience of 100 cases. Int J Urol (2008) 0.75
Laparoscopic adrenalectomy: alternative or new standard? Curr Urol Rep (2002) 0.75
[Usefulness of PSA isoform and related parameter]. Nihon Rinsho (2016) 0.75
Retroperitoneal laparoscopic single-site nephroureterectomy: Initial operative experience. Asian J Endosc Surg (2012) 0.75
Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology (2003) 0.75
[Urachal anomalies and tumor: clinical investigation of 14 cases]. Hinyokika Kiyo (2005) 0.75
Ileal patch graft used to repair a bladder injured during repair of an abdominal wall hernia. Scand J Plast Reconstr Surg Hand Surg (2010) 0.75
[A case of post-traumatic high flow priapism]. Nihon Hinyokika Gakkai Zasshi (2003) 0.75
Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol (2003) 0.75
[Case of congenital bladder diverticulum--cause of urinary retention in adulthood]. Nihon Hinyokika Gakkai Zasshi (2010) 0.75